<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated">
      <PMID Version="1">34624146</PMID>
      <DateCompleted>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>19</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2022</Year>
        <Month>05</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1527-3350</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>75</Volume>
            <Issue>6</Issue>
            <PubDate>
              <Year>2022</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Hepatology (Baltimore, Md.)</Title>
          <ISOAbbreviation>Hepatology</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Macrophage nuclear factor erythroid 2-related factor 2 deficiency promotes innate immune activation by tissue inhibitor of metalloproteinase 3-mediated RhoA/ROCK pathway in the ischemic liver.</ArticleTitle>
        <Pagination>
          <StartPage>1429</StartPage>
          <EndPage>1445</EndPage>
          <MedlinePgn>1429-1445</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1002/hep.32184</ELocationID>
        <Abstract>
          <AbstractText Label="BACKGROUND AND AIMS" NlmCategory="OBJECTIVE">Nuclear factor erythroid 2-related factor 2 (Nrf2) is a master regulator of reactive oxygen species (ROS) and inflammation and has been implicated in both human and murine inflammatory disease models. We aimed to characterize the roles of macrophage-specific Nrf2 in liver ischemia/reperfusion injury (IRI).</AbstractText>
          <AbstractText Label="APPROACH AND RESULTS" NlmCategory="RESULTS">First, macrophage Nrf2 expression and liver injury in patients undergoing OLT or ischemia-related hepatectomy were analyzed. Subsequently, we created a myeloid-specific Nrf2-knockout (Nrf2<sup>M-KO</sup> ) strain to study the function and mechanism of macrophage Nrf2 in a murine liver IRI model. In human specimens, macrophage Nrf2 expression was significantly increased in liver tissues after transplantation or hepatectomy. Interestingly, lower Nrf2 expressions correlated with more severe liver injury postoperatively. In a mouse model, we found Nrf2<sup>M-KO</sup> mice showed worse hepatocellular damage than Nrf2-proficient controls based on serum biochemistry, pathology, ROS, and inflammation. In vitro, Nrf2 deficiency promoted innate immune activation and migration in macrophages on toll-like receptor (TLR) 4 stimulation. Microarray profiling showed Nrf2 deletion caused markedly lower transcriptional levels of tissue inhibitor of metalloproteinase 3 (Timp3). ChIP-seq, PCR, and luciferase reporter assay further demonstrated Nrf2 bound to the promoter region of Timp3. Moreover, a disintegrin and metalloproteinase (ADAM) 10/ROCK1 was specifically increased in Nrf2-deficient macrophages. Increasing Timp3 expression effectively inhibited ADAM10/ROCK1 expression and rescued the Nrf2<sup>M-KO</sup> -mediated inflammatory response on TLR4 stimulation in vitro. Importantly, Timp3 overexpression, recombinant Timp3 protein, or ROCK1 knockdown rescued Nrf2<sup>M-KO</sup> -related liver IRI by inhibiting macrophage activation.</AbstractText>
          <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">In conclusion, macrophage Nrf2 mediates innate proinflammatory responses, attenuates liver IRI by binding to Timp3, and inhibits the RhoA/ROCK pathway, which provides a therapeutic target for clinical organ IRI.</AbstractText>
          <CopyrightInformation>Â© 2021 The Authors. Hepatology published by Wiley Periodicals LLC on behalf of American Association for the Study of Liver Diseases.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rao</LastName>
            <ForeName>Jianhua</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Reproductive Medicine, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Qiu</LastName>
            <ForeName>Jiannan</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ni</LastName>
            <ForeName>Ming</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Hao</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Peng</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhang</LastName>
            <ForeName>Lei</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Zeng</ForeName>
            <Initials>Z</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Mu</ForeName>
            <Initials>M</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Cheng</LastName>
            <ForeName>Feng</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Xuehao</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Reproductive Medicine, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Lu</LastName>
            <ForeName>Ling</ForeName>
            <Initials>L</Initials>
            <AffiliationInfo>
              <Affiliation>Research Unit of Liver Transplantation and Transplant Immunology, Key Laboratory of Liver Transplantation, Chinese Academy of Medical Sciences, Hepatobiliary Center of The First Affiliated Hospital, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>Jiangsu Key Lab of Cancer Biomarkers, Prevention and Treatment, Collaborative Innovation Center for Personalized Cancer Medicine, Nanjing Medical University, Nanjing, China.</Affiliation>
            </AffiliationInfo>
            <AffiliationInfo>
              <Affiliation>State Key Laboratory of Reproductive Medicine, Nanjing, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2021</Year>
          <Month>12</Month>
          <Day>10</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>United States</Country>
        <MedlineTA>Hepatology</MedlineTA>
        <NlmUniqueID>8302946</NlmUniqueID>
        <ISSNLinking>0270-9139</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051267">NF-E2-Related Factor 2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D017382">Reactive Oxygen Species</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C088390">TIMP3 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019717">Tissue Inhibitor of Metalloproteinase-3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>124671-05-2</RegistryNumber>
          <NameOfSubstance UI="C066737">RHOA protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="C515851">ROCK1 protein, human</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.1</RegistryNumber>
          <NameOfSubstance UI="D054460">rho-Associated Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.-</RegistryNumber>
          <NameOfSubstance UI="D045726">Metalloproteases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.6.5.2</RegistryNumber>
          <NameOfSubstance UI="D020742">rhoA GTP-Binding Protein</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007113" MajorTopicYN="Y">Immunity, Innate</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007511" MajorTopicYN="N">Ischemia</DescriptorName>
          <QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008099" MajorTopicYN="Y">Liver</DescriptorName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008264" MajorTopicYN="N">Macrophages</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045726" MajorTopicYN="N">Metalloproteases</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051267" MajorTopicYN="Y">NF-E2-Related Factor 2</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017382" MajorTopicYN="N">Reactive Oxygen Species</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015427" MajorTopicYN="Y">Reperfusion Injury</DescriptorName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019717" MajorTopicYN="N">Tissue Inhibitor of Metalloproteinase-3</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D054460" MajorTopicYN="N">rho-Associated Kinases</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020742" MajorTopicYN="N">rhoA GTP-Binding Protein</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="revised">
          <Year>2021</Year>
          <Month>9</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="received">
          <Year>2021</Year>
          <Month>2</Month>
          <Day>2</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>4</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>9</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2022</Year>
          <Month>5</Month>
          <Day>20</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2021</Year>
          <Month>10</Month>
          <Day>8</Day>
          <Hour>17</Hour>
          <Minute>19</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">34624146</ArticleId>
        <ArticleId IdType="doi">10.1002/hep.32184</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Title>REFERENCES</Title>
        <Reference>
          <Citation>Zhai Y, Petrowsky H, Hong JC, Busuttil RW, Kupiec-Weglinski JW. Ischemia-reperfusion injury in liver transplantation-from bench to bedside. Nat Rev Gastroenterol Hepatol. 2013;10(2):79-89.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhou H, Wang H, Ni M, Yue S, Xia Y, Busuttil RW, et al. Glycogen synthase kinase 3Î² promotes liver innate immune activation by restraining AMP-activated protein kinase activation. J Hepatol. 2018;69(1):99-109.</Citation>
        </Reference>
        <Reference>
          <Citation>Panel M, Ruiz I, Brillet R, Lafdil F, Teixeira-Clerc F, Nguyen CT, et al. Small-molecule inhibitors of cyclophilins block opening of the mitochondrial permeability transition pore and protect mice from hepatic ischemia/reperfusion injury. Gastroenterology. 2019;157(5):1368-82.</Citation>
        </Reference>
        <Reference>
          <Citation>Schwabe RF, Brenner DA. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol. 2006;290(4):G583-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Kamo N, Ke B, Ghaffari AA, Shen XD, Busuttil RW, Cheng G, et al. ASC/caspase-1/IL-1Î² signaling triggers inflammatory responses by promoting HMGB1 induction in liver ischemia/reperfusion injury. Hepatology. 2013;58(1):351-62.</Citation>
        </Reference>
        <Reference>
          <Citation>Rao J, Cheng F, Zhou H, Yang W, Qiu J, Yang C, et al. Nogo-B is a key mediator of hepatic ischemia and reperfusion injury. Redox Biol. 2020;37:101745.</Citation>
        </Reference>
        <Reference>
          <Citation>Hennig P, Garstkiewicz M, Grossi S, Di Filippo M, French LE, Beer HD. The crosstalk between Nrf2 and inflammasomes. Int J Mol Sci. 2018;19(2):562.</Citation>
        </Reference>
        <Reference>
          <Citation>Katsuoka F, Yamamoto M. Small Maf proteins (MafF, MafG, MafK): History, structure, and function. Gene. 2016;586(2):197-205.</Citation>
        </Reference>
        <Reference>
          <Citation>McMahon M, Thomas N, Itoh K, Yamamoto M, Hayes JD. Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron, and the redox-insensitive Neh6 degron. J Biol Chem. 2004;279(30):31556-67.</Citation>
        </Reference>
        <Reference>
          <Citation>Silva-Islas CA, Maldonado PD. Canonical and non-canonical mechanisms of Nrf2 activation. Pharmacol Res. 2018;134:92-9.</Citation>
        </Reference>
        <Reference>
          <Citation>Suzuki T, Yamamoto M. Stress-sensing mechanisms and the physiological roles of the Keap1-Nrf2 system during cellular stress. J Biol Chem. 2017;292(41):16817-24.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu M, Grigoryev DN, Crow MT, Haas M, Yamamoto M, Reddy SP, et al. Transcription factor Nrf2 is protective during ischemic and nephrotoxic acute kidney injury in mice. Kidney Int. 2009;76(3):277-85.</Citation>
        </Reference>
        <Reference>
          <Citation>Warpsinski G, Smith MJ, Srivastava S, Keeley TP, Siow RCM, Fraser PA, et al. Nrf2-regulated redox signaling in brain endothelial cells adapted to physiological oxygen levels: Consequences for sulforaphane mediated protection against hypoxia-reoxygenation. Redox Biol. 2020;37:101708.</Citation>
        </Reference>
        <Reference>
          <Citation>Ashrafian H, Czibik G, Bellahcene M, AksentijeviÄ D, Smith A, Mitchell S, et al. Fumarate is cardioprotective via activation of the Nrf2 antioxidant pathway. Cell Metab. 2012;15(3):361-71.</Citation>
        </Reference>
        <Reference>
          <Citation>Parada E, Buendia I, LeÃ³n R, Negredo P, Romero A, Cuadrado A, et al. Neuroprotective effect of melatonin against ischemia is partially mediated by alpha-7 nicotinic receptor modulation and HO-1 overexpression. J Pineal Res. 2014;56(2):204-12.</Citation>
        </Reference>
        <Reference>
          <Citation>Wei Y, Gong J, Yoshida T, Eberhart CG, Xu Z, Kombairaju P, et al. Nrf2 has a protective role against neuronal and capillary degeneration in retinal ischemia-reperfusion injury. Free Radic Biol Med. 2011;51(1):216-24.</Citation>
        </Reference>
        <Reference>
          <Citation>Calvert JW, Jha S, Gundewar S, Elrod JW, Ramachandran A, Pattillo CB, et al. Hydrogen sulfide mediates cardioprotection through Nrf2 signaling. Circ Res. 2009;105(4):365-74.</Citation>
        </Reference>
        <Reference>
          <Citation>Sun Q, Meng QT, Jiang Y, Xia ZY. Ginsenoside Rb1 attenuates intestinal ischemia reperfusion induced renal injury by activating Nrf2/ARE pathway. Molecules. 2012;17(6):7195-205.</Citation>
        </Reference>
        <Reference>
          <Citation>Ke B, Shen XD, Zhang YU, Ji H, Gao F, Yue S, et al. KEAP1-NRF2 complex in ischemia-induced hepatocellular damage of mouse liver transplants. J Hepatol. 2013;59(6):1200-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Yi Z, Deng M, Scott MJ, Fu G, Loughran PA, Lei Z, et al. Immune-responsive gene 1/itaconate activates nuclear factor erythroid 2-related factor 2 in hepatocytes to protect against liver ischemia-reperfusion injury. Hepatology. 2020;72(4):1394-411.</Citation>
        </Reference>
        <Reference>
          <Citation>Rao J, Qian X, Li G, Pan X, Zhang C, Zhang F, et al. ATF3-mediated NRF2/HO-1 signaling regulates TLR4 innate immune responses in mouse liver ischemia/reperfusion injury. Am J Transplant. 2015;15(1):76-87.</Citation>
        </Reference>
        <Reference>
          <Citation>Lv Z, Xu X, Sun Z, Yang YX, Guo HU, Li J, et al. TRPV1 alleviates osteoarthritis by inhibiting M1 macrophage polarization via Ca2+/CaMKII/Nrf2 signaling pathway. Cell Death Dis. 2021;12(6):504.</Citation>
        </Reference>
        <Reference>
          <Citation>Wall SB, Li R, Butler B, Burg AR, Tse HM, Larson-Casey JL, et al. Auranofin-mediated NRF2 induction attenuates interleukin 1 beta expression in alveolar macrophages. Antioxidants (Basel). 2021;10(5):632.</Citation>
        </Reference>
        <Reference>
          <Citation>Ko E, Kim D, Min DW, Kwon SH, Lee JY. Nrf2 regulates cell motility through RhoA-ROCK1 signalling in non-small-cell lung cancer cells. Sci Rep. 2021;11(1):1247.</Citation>
        </Reference>
        <Reference>
          <Citation>Zhang C, Wang H-J, Bao Q-C, Wang L, Guo T-K, Chen W-L, et al. NRF2 promotes breast cancer cell proliferation and metastasis by increasing RhoA/ROCK pathway signal transduction. Oncotarget. 2016;7(45):73593-606.</Citation>
        </Reference>
        <Reference>
          <Citation>Ke B, Shen XD, Gao F, Ji H, Qiao BO, Zhai Y, et al. Adoptive transfer of ex vivo HO-1 modified bone marrow-derived macrophages prevents liver ischemia and reperfusion injury. Mol Ther. 2010;18(5):1019-25.</Citation>
        </Reference>
        <Reference>
          <Citation>Yue S, Zhu J, Zhang M, Li C, Zhou X, Zhou M, et al. The myeloid heat shock transcription factor 1/Î²-catenin axis regulates NLR family, pyrin domain-containing 3 inflammasome activation in mouse liver ischemia/reperfusion injury. Hepatology. 2016;64(5):1683-98.</Citation>
        </Reference>
        <Reference>
          <Citation>Tang ZY, Loss G, Carmody I, Cohen AJ. TIMP-3 ameliorates hepatic ischemia/reperfusion injury through inhibition of tumor necrosis factor-alpha-converting enzyme activity in rats. Transplantation. 2006;82(11):1518-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Rao J, Yue S, Fu Y, Zhu J, Wang X, Busuttil RW, et al. ATF6 mediates a pro-inflammatory synergy between ER stress and TLR activation in the pathogenesis of liver ischemia-reperfusion injury. Am J Transplant. 2014;14(7):1552-61.</Citation>
        </Reference>
        <Reference>
          <Citation>McMahon M, Itoh K, Yamamoto M, Hayes JD. Keap1-dependent proteasomal degradation of transcription factor Nrf2 contributes to the negative regulation of antioxidant response element-driven gene expression. J Biol Chem. 2003;278(24):21592-600.</Citation>
        </Reference>
        <Reference>
          <Citation>Cullinan SB, Gordan JD, Jin J, Harper JW, Diehl JA. The Keap1-BTB protein is an adaptor that bridges Nrf2 to a Cul3-based E3 ligase: oxidative stress sensing by a Cul3-Keap1 ligase. Mol Cell Biol. 2004;24(19):8477-86.</Citation>
        </Reference>
        <Reference>
          <Citation>Corsello T, Komaravelli N, Casola A. Role of Hydrogen Sulfide in NRF2- and Sirtuin-Dependent Maintenance of Cellular Redox Balance. Antioxidants (Basel). 2018;7(10):129.</Citation>
        </Reference>
        <Reference>
          <Citation>Jones DP. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol. 2008;295(4):C849-68.</Citation>
        </Reference>
        <Reference>
          <Citation>Rangasamy T, Guo J, Mitzner WA, Roman J, Singh A, Fryer AD, et al. Disruption of Nrf2 enhances susceptibility to severe airway inflammation and asthma in mice. J Exp Med. 2005;202(1):47-59.</Citation>
        </Reference>
        <Reference>
          <Citation>Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, IIzuka T, et al. Transcription factor Nrf2 plays a pivotal role in protection against elastase-induced pulmonary inflammation and emphysema. J Immunol. 2005;175(10):6968-75.</Citation>
        </Reference>
        <Reference>
          <Citation>Thimmulappa RK, Lee H, Rangasamy T, Reddy SP, Yamamoto M, Kensler TW, et al. Nrf2 is a critical regulator of the innate immune response and survival during experimental sepsis. J Clin Invest. 2006;116(4):984-95.</Citation>
        </Reference>
        <Reference>
          <Citation>Mossanen JC, Krenkel O, Ergen C, Govaere O, Liepelt A, Puengel T, et al. Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen-induced acute liver injury. Hepatology. 2016;64(5):1667-82.</Citation>
        </Reference>
        <Reference>
          <Citation>Starkey Lewis P, Campana L, Aleksieva N, Cartwright JA, Mackinnon A, O'Duibhir E, et al. Alternatively activated macrophages promote resolution of necrosis following acute liver injury. J Hepatol. 2020;73(2):349-60.</Citation>
        </Reference>
        <Reference>
          <Citation>Takawale A, Sakamuri SS, Kassiri Z. Extracellular matrix communication and turnover in cardiac physiology and pathology. Compr Physiol. 2015;5(2):687-719.</Citation>
        </Reference>
        <Reference>
          <Citation>Fan D, Kassiri Z. Biology of tissue inhibitor of metalloproteinase 3 (TIMP3), and its therapeutic implications in cardiovascular pathology. Front Physiol. 2020;11:661.</Citation>
        </Reference>
        <Reference>
          <Citation>Jiang JX, Chen X, Fukada H, Serizawa N, Devaraj S, TÃ¶rÃ¶k NJ. Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-Î±-converting enzyme activity in mice. Hepatology. 2013;58(4):1339-48.</Citation>
        </Reference>
        <Reference>
          <Citation>Defamie V, Sanchez O, Murthy A, Khokha R. TIMP3 controls cell fate to confer hepatocellular carcinoma resistance. Oncogene. 2015;34(31):4098-108.</Citation>
        </Reference>
        <Reference>
          <Citation>Azar F, Courtet K, Dekky B, Bonnier D, Dameron O, Colige A, et al. Integration of miRNA-regulatory networks in hepatic stellate cells identifies TIMP3 as a key factor in chronic liver disease. Liver Int. 2020;40(8):2021-33.</Citation>
        </Reference>
        <Reference>
          <Citation>Fujii T, Duarte S, Lee E, Ke B, Busuttil RW, Coito AJ. Tissue inhibitor of metalloproteinase 3 deficiency disrupts the hepatocyte E-cadherin/Î²-catenin complex and induces cell death in liver ischemia/reperfusion injury. Liver Transpl. 2020;26(1):113-26.</Citation>
        </Reference>
        <Reference>
          <Citation>Kassiri Z, Oudit GY, Kandalam V, Awad A, Wang X, Ziou X, et al. Loss of TIMP3 enhances interstitial nephritis and fibrosis. J Am Soc Nephrol. 2009;20(6):1223-35.</Citation>
        </Reference>
        <Reference>
          <Citation>Liu H, Jing X, Dong A, Bai B, Wang H. Overexpression of TIMP3 protects against cardiac ischemia/reperfusion injury by inhibiting myocardial apoptosis through ROS/Mapks pathway. Cell Physiol Biochem. 2017;44(3):1011-23.</Citation>
        </Reference>
        <Reference>
          <Citation>Shimoda M, Principe S, Jackson HW, Luga V, Fang H, Molyneux SD, et al. Loss of the Timp gene family is sufficient for the acquisition of the CAF-like cell state. Nat Cell Biol. 2014;16(9):889-901.</Citation>
        </Reference>
        <Reference>
          <Citation>Montezano AC, Callera GE, Yogi A, He Y, Tostes RC, He G, et al. Aldosterone and angiotensin II synergistically stimulate migration in vascular smooth muscle cells through c-Src-regulated redox-sensitive RhoA pathways. Arterioscler Thromb Vasc Biol. 2008;28(8):1511-8.</Citation>
        </Reference>
        <Reference>
          <Citation>Kondrikov D, Caldwell RB, Dong Z, Su Y. Reactive oxygen species-dependent RhoA activation mediates collagen synthesis in hyperoxic lung fibrosis. Free Radic Biol Med. 2011;50(11):1689-98.</Citation>
        </Reference>
        <Reference>
          <Citation>Segain JP, Raingeard de la BlÃ©tiÃ¨re D, Sauzeau V, Bourreille A, Hilaret G, Cario-Toumaniantz C, et al. Rho kinase blockade prevents inflammation via nuclear factor kappa B inhibition: evidence in Crohn's disease and experimental colitis. Gastroenterology. 2003;124(5):1180-7.</Citation>
        </Reference>
        <Reference>
          <Citation>Mong PY, Wang Q. Activation of Rho kinase isoforms in lung endothelial cells during inflammation. J Immunol. 2009;182(4):2385-94.</Citation>
        </Reference>
        <Reference>
          <Citation>Kuroda S, Tashiro H, Igarashi Y, Tanimoto Y, Nambu J, Oshita A, et al. Rho inhibitor prevents ischemia-reperfusion injury in rat steatotic liver. J Hepatol. 2012;56(1):146-52.</Citation>
        </Reference>
        <Reference>
          <Citation>Lu L, Yue S, Jiang L, Li C, Zhu Q, Ke M, et al. Myeloid Notch1 deficiency activates the RhoA/ROCK pathway and aggravates hepatocellular damage in mouse ischemic livers. Hepatology. 2018;67(3):1041-55.</Citation>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
